Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax (Nasdaq: ABVX / Euronext: FR0012333284) filed its Universal Registration Document with the Autorité des Marchés Financiers and its Annual Report (Form 20-F) with the U.S. SEC. The 20-F filing date was March 23, 2026.The Universal Registration Document contains the 2025 annual financial report, management and corporate governance reports, and statutory auditors' reports. Documents are available for download on Abivax, AMF, and SEC websites.

#ABVX Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

www.stocktitan.net/news/ABVX/abivax-publish...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates Abivax (NASDAQ:ABVX) reported full-year 2025 results and program updates on March 23, 2026. Key highlights include €530.4M cash and short-term investments (runway into Q4 2027), completion of a $700.3M net US offering, and a DSMB safety review reporting no new safety signals for the Phase 3 ABTECT-UC maintenance trial.The Company remains on track to report topline ABTECT-UC maintenance results in late Q2 2026, appointed a new Chief Commercial Officer, and reported a 2025 net loss of €336.1M.

#ABVX Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/ABVX/abivax-announc...

GitHub - markoblogo/lab.abvx: ABVX Lab — a small static hub of ABVX developer tools (GitHub Pages). ABVX Lab — a small static hub of ABVX developer tools (GitHub Pages). - markoblogo/lab.abvx

First public release v0.1.2-test: lab.abvx
ABVX Lab — a small static hub of ABVX developer tools (GitHub Pages).
https://github.com/markoblogo/lab.abvx?preview=v2
#abvx #aitools

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OKLO, #ABVX, #BMNR, #ORCL, #BE

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #VKTX 112% OTM
2. #ABVX 44% OTM
3. #NIO 39% OTM
4. #CORT 29% OTM
5. #UEC 27% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VKTX, #ABVX, #NIO, #CORT, #UEC

#OptionFlow #OptionsTrading #Trading

#ABVX slid ~10% in Paris and ~7% in New York after the company reported a wider 2025 loss tied to late-stage trials of its lead drug, obefazimod. The pullback comes after a 1,200%+ YTD surge driven by ulcerative colitis trial success and takeover speculation involving Eli Lilly.

French biotech Abivax rides upbeat data, takeover speculation to 1,400% YTD gain – Oninvest Shares of European biotech Abivax SA have surged almost 1,400% year to date on the Paris exchange, with its market capitalization now above EUR7.5 billion. Investors are buying the stock, considering ...

🚀 #ABVX has surged ~1,400% YTD, the STOXX 600’s best performer, after strong Phase III data for its colitis drug obefazimod. Investors now see it as a prime takeover target. Details: en.oninvest.com/article/fren...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies Abivax (NASDAQ:ABVX) announced late‑breaking pooled results from the Phase 3 ABTECT 8‑Week induction trials for obefazimod presented at UEG on October 6, 2025. The PR states that once‑daily 50 mg obefazimod produced clinically meaningful improvements across clinical, endoscopic, and histologic endpoints in populations with and without prior advanced‑therapy inadequate response (AT‑IR). In pooled ABTECT‑1&2 (N=1,272), placebo‑adjusted clinical response differences included +28% (no prior AT‑IR, p<0.0001), +29% (4+ prior AT‑IR, p=0.0242) and +34% (prior JAK inhibitor failure, p=0.0017). The company states obefazimod was well tolerated with no new safety signals. Management hosted a conference call the same day to discuss topline results.

#ABVX Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

www.stocktitan.net/news/ABVX/abivax-announc...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data Abivax (NASDAQ:ABVX) announced late-breaking results from the Phase 3 ABTECT 8-week induction trials for obefazimod presented Oct 5, 2025 at UEG. The PR states the pooled 50 mg once-daily dose produced a 16.4% placebo-adjusted clinical remission rate at Week 8 (p<0.0001) and that both ABTECT 1 and 2 met the FDA primary endpoint and all key secondary endpoints at 50 mg.The trials enrolled 1,272 patients with a refractory population (47% with prior inadequate response to advanced therapy; 21% with prior JAK inhibitor inadequate response). The PR reports no signal for serious, severe, or opportunistic infections or malignancies and provides updated TEAE rates by dose.

#ABVX Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

www.stocktitan.net/news/ABVX/abivax-announc...

Key Phase 3 Results Coming: Abivax's Novel UC Drug Obefazimod Data to be Revealed at Major EU Conference Biotech firm Abivax will present Phase 3 ABTECT trial results for obefazimod in ulcerative colitis at UEG 2025, including data on patients with prior treatment resistance. Symposium scheduled Oct 6.

#ABVX Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

www.stocktitan.net/news/ABVX/abivax-announc...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax (NASDAQ:ABVX) has announced the pricing of its public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per ADS, aiming to raise approximately $650 million. The company has also granted underwriters a 30-day option to purchase up to 1,523,400 additional ADSs.The offering price represents a 21% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris. The proceeds will primarily fund the clinical development of obefazimod for Ulcerative Colitis ($140-185 million) and Crohn's Disease ($30-65 million). Combined with current cash reserves of $71.4 million, this funding is expected to extend operations into Q4 2027.The offering will result in approximately 16% dilution of share capital, or 18.4% if the underwriters' option is fully exercised. A 60-day lock-up period applies to both company executives and the company itself.

#ABVX Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

www.stocktitan.net/news/ABVX/abivax-announc...

Abivax Trading Resumes Following Major US Public Offering Launch: What Investors Should Know French biotech Abivax resumes trading on Euronext Paris following temporary halt for US public offering. Learn about this strategic expansion move. Get details now.

#ABVX Abivax announces trading resumption of its ordinary shares on Euronext Paris

www.stocktitan.net/news/ABVX/abivax-announc...

Abivax Suspends European Trading to Launch Major US Stock Offering: Key Details Inside Temporary trading halt until 3:30 PM CEST as Abivax prepares for US public offering of American Depositary Shares. Get full details on the strategic pause.

#ABVX Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

www.stocktitan.net/news/ABVX/abivax-announc...

Breaking News: ( NASDAQ: #ABVX ) US Companies Moving the Markets, Evening edition <br>Wed, Jul 23, 2025 as of 4:00 pm ET

Abivax Announces Launch of Public Offering Abivax (NASDAQ:ABVX) has announced the launch of a significant $400 million (€340 million) public offering of American Depositary Shares (ADSs) in the United States. Each ADS represents one ordinary share of the company. The offering includes a 30-day option for underwriters to purchase up to 15% additional ADSs.The company plans to use the proceeds primarily for: 23% for obefazimod development in Ulcerative Colitis, 5% for Crohn's Disease development, and 72% for working capital and general corporate purposes. As of June 30, 2025, Abivax had cash reserves of $71.4 million, sufficient to fund operations into Q4 2025.Additionally, Heights Capital Management has submitted a notice to convert 150 convertible notes (€9.4 million) into 394,447 new ordinary shares at €23.7674 per share, with issuance expected around July 29, 2025.

#ABVX Abivax Announces Launch of Public Offering

www.stocktitan.net/news/ABVX/abivax-announc...

NEWS: ( NASDAQ: #ABVX ) Meme Stocks vs. Tight-Float Contender and Other Headlines

BREAKING NEWS: ( NASDAQ: #ABVX ) ABVX Price Target Alert: $74.00. Issued by Leerink Partners

NEWS: ( NASDAQ: #ABVX ) Outperform Recommendation Issued On ABVX By Leerink Partners

Just In: ( NASDAQ: #ABVX ) US Companies Moving the Markets, Morning edition <br>Wed, Jul 23, 2025 as of 10.00 am ET

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks overbought with declining relative strength, Mon Jun 9th - #GRPN #INDV #LYRA #SGHT #ABVX #FMST #MHUA #ROMA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Abivax Presents First Quarter 2025 Financial Results Abivax (ABVX) reported Q1 2025 financial results, showing increased operating losses of EUR 47.2M compared to EUR 44.7M in Q1 2024. R&D expenses rose by EUR 3.6M to EUR 39.3M, primarily due to Crohn's Disease clinical program progression and expanded R&D headcount. The company recorded a net loss of EUR 52.4M, up from EUR 42.9M in Q1 2024. Cash position decreased to EUR 103.6M from EUR 144.2M at year-end 2024, with current funding expected to sustain operations into Q4 2025. Notable operational progress includes completion of Phase 3 ABTECT trial enrollment for ulcerative colitis treatment and advancement of Crohn's Disease clinical programs.

#ABVX Abivax Presents First Quarter 2025 Financial Results

www.stocktitan.net/news/ABVX/abivax-present...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Thu May 22nd - #BON #ABVX #XAGE #VALN #TIL #SABS #QMCO #NVTS #IOBT #HOOK #CREX #FGL #DOMO #CNCK #BDRX #AMSC #VCSA #SMWB #AAP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax (ABVX) has announced its Annual General Meeting scheduled for June 6, 2025, in Paris, France. The company provided updates on its key operational milestones, particularly highlighting the progress of its Phase 3 ABTECT clinical program. Enrollment completion for the ABTECT induction trials is expected in Q2 2025, with top-line induction results anticipated in Q3 2025.In a show of confidence in the company's future, CEO Marc de Garidel revealed that the executive leadership team, including himself, invested in approximately 120,000 Abivax ordinary shares in Q1 2025. The company, which focuses on developing therapeutics for chronic inflammatory diseases, views 2025 as a potentially transformative year with major clinical readouts approaching.

#ABVX Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

www.stocktitan.net/news/ABVX/abivax-announc...

Abivax Annual Reports Reveal Latest Progress on Key Phase 3 Ulcerative Colitis Drug New financial filings detail Abivax's advancement of obefazimod Phase 3 trials for ulcerative colitis treatment. Access full reports on AMF and SEC platforms.

#ABVX Abivax publishes financial reports with the French and U.S. securities regulatory agencies

www.stocktitan.net/news/ABVX/abivax-publish...

Abivax Financial Results: EUR 144M War Chest Powers Pivotal UC Drug Trial Strong EUR 144.2M cash runway into Q4 2025 fuels Phase 3 ABTECT trial progress. Key UC treatment milestones set for 2025. Full analysis inside.

#ABVX Abivax Announces Full Year 2024 Financial Results

www.stocktitan.net/news/ABVX/abivax-announc...

Abivax's Complete 2025 Financial Roadmap: All Critical Dates for Your Investment Planning Clinical-stage biotech Abivax reveals comprehensive 2025 financial reporting schedule, including annual results, quarterly updates, and AGM dates for both US and European markets.

#ABVX Abivax Publishes 2025 Financial Calendar

www.stocktitan.net/news/ABVX/abivax-publish...